Key Takeaways
- Domestic formulation outperformed, exports dragged: Standalone growth of ~5% missed the 10.5-11% guidance entirely because export formulations and APIs declined, while the domestic business grew 12% and gained market share.
- Margins beat guidance on mix and cost control: Standalone EBITDA reached 22.25% (vs 21% guided) and consolidated 18.52% (vs 18% guided), helped by a favourable product mix shift away from lower-margin API and tight operating expenditure.
- Full-year growth guidance cut to ~9%: The Q1 export shortfall is not bridgeable; management now expects standalone growth around 9% for FY25, down from 10.5-11%, though Q2 should deliver the originally guided rate.
- Unichem turnaround is a multi-quarter story: Gross margins are improving through procurement synergies and logistics fixes, but regulatory filings and market extensions mean material benefits are 1.5-2 years away.
- What to watch next quarter: Whether the promised Q2 growth rebound materialises, the pace of export logistics normalisation, and any further margin upside beyond the already-raised guidance.
Domestic Formulation: The Standout Engine
- Market-beating growth: The domestic formulation business grew 12% against IPM growth of 9%, with outperformance in both acute and chronic segments.
- Market share gains: MAT June 2024 market share crossed 2.01%, up from 1.91% a year ago; the Q1 share reached 2.17% versus 2.06% in Q1 FY24, a gain of roughly 11 bps.
- Field force productivity rising: MR productivity improved from ₹4.21 lakhs to ₹4.52 lakhs per month even as the field staff headcount increased.
- New division launch imminent: A new pain-focused division will be launched in the market within the next two months, adding a fresh growth lever.
Export & API: The Drag on Performance
- Export formulation declined 1%: The drop was driven by major challenges in shipping, container availability, and broader supply chain disruptions.
- API business declined 2%: Continued challenges weighed on the segment, and the lower API contribution had the side-effect of improving the overall product mix and gross margin.
- Australia/New Zealand hit hard: Business in this geography fell by almost ₹40 crores due to an API-side supply chain issue; supplies may resume this quarter with revenue recovery expected from Q3 onwards.
- Logistics normalisation is slow: Management cautioned that the ground situation has not improved yet and export logistics issues will take more time to resolve, though exports will certainly improve.
Margins: Beating Guidance with Mix and Cost Discipline
- Both standalone and consolidated margins exceeded guidance: Standalone EBITDA came in at 22.25% (vs ~21% guided) and consolidated at 18.52% (vs ~18% guided).
- The margin drivers: A better product mix (lower share of low-margin API), lower input costs, and tight control on operating costs, with manufacturing expenditure growing just 2% and employment costs around 9%.
- Price erosion has stabilised: Management noted price erosion is now very limited (2-3% in pockets) and the trend has stopped; input costs are stable with marginal improvement in solvents.
- Further upside flagged: Margins could end the year around 0.5 to 1 percentage point higher than the earlier guidance, implying standalone EBITDA of 20.5-21% and consolidated around 18.5%.
Unichem Integration: Early Gains, Long Road Ahead
- Gross margins already improving: Procurement pricing has been substantially reduced by combining IPCA and Unichem volumes, alongside operating efficiencies and utility cost improvements.
- Logistics mix transformed: The air/sea freight split has been reversed from 60% air and 40% sea to just 17-18% air, though sea freight costs have moved up roughly 3x, partially offsetting the benefit.
- Cost of production reductions in the pipeline: Some intermediates that reduce cost of production are under development and will be commercialised in the next two quarters.
- Market extensions are a 1.5-2 year journey: Extending Unichem products to Europe, Latin America, Australia/New Zealand, and Canada requires regulatory filings, reviews, query responses, approvals, and marketing preparations, a process management explicitly frames as a long haul.
A.K. Jain: "Nothing is going to come very quickly because a lot of work are happening, the other compilations are going on. They will be filed with regulators. And once they review and whatever their queries are there, that replied, only after then, we will get the approvals and then marketing preparations, all that. So, it's a 1.5 to 2 years kind of journey."
U.S. Generics: A Constructive Environment, Gradual Build
- Pricing pressure has eased materially: Management described only marginal pricing pressure and stated the U.S. is no longer seeing a bloodbath, calling it a better time for the generic business overall.
- Launch cadence building: Two products have already been launched this year; at least 3-4 more are expected in FY25, taking the total to 5-6 for the year, with another 6-7 next year and roughly 12-13 products cumulatively over the next two years.
- New ANDA filings still months away: The company is perhaps 6-8 months away from filing anything new in the U.S., so the near-term pipeline relies on already-filed products.
A.K. Jain: "So, there is not much of pricing pressure. Its only marginal pressures are there. But otherwise, let's say, the U.S. is a good market, and we are not seeing that kind of bloodbath now. So, it's a better time for this generic business overall."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone revenue growth | ~9% (revised down from 10.5-11%) | FY25 full year |
| Q2 standalone growth | Deliver 10.5-11% growth rate | Q2 FY25 |
| Standalone EBITDA margin | 20.5-21% (upside of 0.5-1 pp vs earlier ~21% guide) | FY25 full year |
| Consolidated EBITDA margin | ~18.5% (upside of 0.5-1 pp vs earlier ~18% guide) | FY25 full year |
| U.S. product launches | 5-6 total launches (2 done, 3-4 more) | FY25 |
| U.S. product launches | 6-7 additional launches | FY26 |
| New pain division launch | Division deployed in market | Within 2 months |
| Australia/NZ revenue recovery | Supplies resume, revenue from Q3 | Q2-Q3 FY25 |
| Unichem double-digit growth | Achieve double-digit growth rate | No date (aspiration) |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Standalone revenue growth | ~5%, lower than guidance of 10.5% to 11% |
| Domestic formulation growth | ~12% |
| Export formulation revenue | ₹395 cr, decline of 1% from ~₹398 cr in Q1 FY24 |
| API business revenue | ~₹287 cr, decline of 2% from ₹295 cr in Q1 FY24 |
| Standalone EBITDA margin | 22.25%, better than guidance of 21% for FY25 |
| Consolidated EBITDA margin | ~18.52%, better than guidance of ~18% for FY25 |
| Full-year standalone revenue growth guidance | ~9%, revised from earlier projection of 10.5% to 11% |
| Full-year standalone EBITDA margin guidance | 20.5% to 21%, with possibility of 0.5 to 1 basis point improvement |
| Full-year consolidated EBITDA margin guidance | ~18.5% |
| IPCA IQVIA growth (Q1 FY25) | 15%, versus IPM growth of ~9% |
| Acute segment growth (IQVIA) | ~12%, versus IPM acute growth of ~8% |
| Chronic segment growth (IQVIA) | ~20%, versus IPM chronic growth of 11% |
| Market share (MAT June 2024) | ~2.01%, up from 1.91% in MAT June 2023 |
| Market share (Q1 FY25) | ~2.17%, up from 2.06% in Q1 FY24, a gain of ~11 bps |
| MR strength | ~6,500, up from a little less than 6,000 last year |
| MR productivity per month | ~₹4.52 lakhs, up from ₹4.21 lakhs in Q1 last year |
| Australia/New Zealand revenue decline | ~₹40 cr decline in Q1 FY25 |
| U.S. products launched (cumulative, current FY) | 5 to 6 products expected by year-end; 2 already launched |
| U.S. products launched (cumulative, next 2 years) | 12 to 13 products expected |
| Unichem U.S. air freight share | 17% to 18%, reversed from earlier 60% air and 40% sea |
| Sea freight cost increase | ~3x |